DJ Doran for Mayor of Chicago lgbtq candidate Feb 2023 election politics political race Dennis Velco OutBuro Voice Show Podcast

DJ Doran for Chicago Mayor – Discusses Key Issues

In this episode of OutBüro Voices featuring LGBTQ professionals, entrepreneurs, and community leaders from around the world, host Dennis Velco chats with DJ Doran, a media entrepreneur, LGBTQ community organizer, 23 year US Airforce veteran, and long-time Chicago citizen.

Chicago News: Breaking DJ Doran announces his candidacy for Mayor of Chicago. (April 6, 2022). The election is in February 2023.

Mayoral candidate DJ Doran has never held a public office, his background is well suited to tackle the big issues Chicago faces. In our conversation, Doran lists 7 key issues and the practical high-level steps he’d take toward improving life for everyone in Chicago. As he explains, the first step would be to assess the current situation by meeting with the 50 Alderman, and city key departments, auditing the city finances and auditing the city contracts, policies, processes, and systems. He will empower the great employees of the City of Chicago to work with him to make Chicago a well-run city where all have the opportunity to thrive in a safe environment.

For many, like myself, as soon as I hear “Chicago Politics” the first word that pops in my mind is “corruption”. I thought that maybe I’d seen too many movies. However, as Doran discussed the issues Chicago faces, that knee-jerk thought seems to unfortunately still be quite real. Compounding the issues is Mayor Lightfoot who is ineffective at best.

The system is full of career politicians who generally have little business life experience only appear to have their egos in mind. It would be nice to be proven wrong on that. The city has contracts that no reasonable business owner would ever sign such as a 100-year parking meter contract. WHAT? I’d love to see that agreement to pick it apart. How could any competent person working in good faith for the city do such a thing? It was a political hack job with only the crony politician who forced that through and the parking meter company’s bank account benefiting. DJ states that if he ran his business finances the way the City of Chicago currently does, he’d be in JAIL! The people of Chicago deserve a city government and leaders that have the community at large best interests in mind. DJ Doran is the right person for the job.

Learn more about DJ Doran and the issues Chicago faces at:



Read more on Windy City Times: https://www.windycitytimes.com/lgbt/POLITICS-Gay-media-owner-to-run-for-Chicago-mayor/72852.html

Chicago deserves better than Mayor Lightfoot who said: ‘I have the biggest d*** in Chicago’Mayor Lightfoot is being sued for defamation, accused of profane comments – see news story here – https://www.youtube.com/watch?v=GpIQ2E4gXj0

Join us on OutBüro, the LGBTQ professional and entrepreneur online community network for gay, lesbian, bisexual, transgender, queer, allies, and our employers who support LGBTQ welcoming workplace equality-focused benefits, policies, and business practices. https://www.OutBuro.com

Would you like to be featured like this? Contact the host Dennis Velco via our site’s Recommend an Interview Guest form. https://outburo.com/recommend-a-guest/

Less than Half of U.S. Workers Believe New Vaccine Mandates Will Be Enforced Qualtrics Study Finds OutBuro lgbtq professional entreprenuer networking online community gay lesbian transgender queer

Less than Half of U.S. Workers Believe New Vaccine Mandates Will Be Enforced, Qualtrics Study Finds

55% of people say they will consider reporting a coworker for violating a vaccine mandate

Companies are at risk of losing employees with 75% of unvaccinated workers saying they are considering leaving their current place of employment when mandates go into effect

PROVO, Utah & SEATTLE–(BUSINESS WIRE)–New research from Qualtrics (Nasdaq: XM) reveals that less than half of U.S. workers believe their employers or the government will effectively enforce federal vaccine mandates. Even though a majority of employees (58%) support President Biden’s proposed vaccine requirements, which are meant to slow the spread of COVID-19 and its variants, just 49% believe the federal government will be able to effectively enforce them for private companies. The full results of the study can be found here.

QualtricsXM RBG

While federal vaccine mandates are still in final review, 60% of employees say vaccine mandates or discussion about them have caused contention at their place of work. Employees say that conversations around vaccinations are affecting company culture and productivity in the form of decreased trust among coworkers and managers, and the formation of groups or cliques. Once the mandates are enforced, division may become an even bigger problem for workplace culture as 55% of employees say they would consider reporting a coworker to OSHA for violating a vaccine mandate.

Still, most (58%) of unvaccinated workers are not afraid of losing their jobs if they don’t comply with vaccine rules. Only 12% say the risk of being fired would convince them to get the vaccine anyway. On the other hand, at a time when retention is a top priority for business leaders experiencing the effects of The Great Resignation, 75% of unvaccinated people say they would consider leaving their jobs if vaccine mandates are put into place. If unvaccinated workers do find themselves out of a job, 13% say they will retire or take a break from work, potentially adding to the current labor shortage. Larger percentages however will look for new jobs — 22% at smaller companies and 32% at companies with over 100 employees that are not as strict about vaccination.

“In order for these rules to be most effective, people have to trust that they will be enforced. This will be a challenge for leaders as they roll out new vaccine requirements,” said Sydney Heimbrock, Chief Industry Advisor for Government, Qualtrics. “It’s crucial that employers understand and anticipate how their workers will react to new policies. The way in which organizations roll out their strategies, and how they are listening to their employees, are crucial to success and to preventing unwanted turnover.”

More key findings:

  • Politics may influence company policies: 84% of employees say politics affect their company’s vaccine, mask and testing policies — with 42% saying politics has a negative impact on company decision making and 22% saying it has a positive impact.
  • Unvaccinated people are unlikely to be swayed by federal mandates: Only 7% of unvaccinated people say a law or executive order would motivate them to get the vaccine, and 52% of unvaccinated people say mandates would make them less likely to get vaccinated.
  • Tech employees are most supportive of federal mandates: 74% of tech and IT workers support the proposed federal vaccine mandates, and government workers are the least supportive at 51%. 56% of healthcare workers, 54% of retail employees and 54% of those employed in the Travel, Hospitality and Food industries support all of the mandates the Biden Administration has announced.
  • Most employees feel comfortable talking about their vaccine status with coworkers: 53% feel comfortable talking about their vaccination status with coworkers vs. 25% who feel uncomfortable. The main reason people feel uncomfortable is “it’s personal information.”
  • Employees are split on enforcement: 42% of employees want their company leadership to enforce federal vaccine mandates, while 39% do not want them to enforce the new regulations.


This study was fielded between Oct. 12 and Oct. 15, 2021. Respondents were selected from a randomized panel and considered eligible if they live in the United States, are at least 18 years of age and are employed full time or part time. The total number of respondents was 1,309. Respondents who did not pass quality standards were removed.

For the full results of this study, please visit: http://qualtrics.com/blog/fall-vaccine-research-2021

To learn more about Qualtrics’ Vaccination and Testing manager, click here.

About Qualtrics

Qualtrics, the leader and creator of the Experience Management (XM) category, is changing the way organizations manage and improve the four core experiences of business—customer, employee, product and brand. Over 13,500 organizations around the world use Qualtrics to listen, understand and take action on experience data (X-data™)—the beliefs, emotions and intentions that tell you why things are happening, and what to do about it. The Qualtrics XM Platform™ is a system of action that helps businesses attract customers who stay longer and buy more, engage employees who build a positive culture, develop breakthrough products people love and build a brand people are passionate about. To learn more, please visit qualtrics.com.


Press Contact
Erica Evans


Nearly 2-in-5 Hospitality Workers Considering or Have Plans to Leave Their Job in the Next Two Months OutBuro lgbtq professional entreprenuer networking online community gay lesbian queer

Nearly 2-in-5 Hospitality Workers Considering or Have Plans to Leave Their Job in the Next Two Months

Medallia Zingle report finds a quarter of global hospitality employees say their employee experience has suffered since the return to travel.

SAN FRANCISCO–(BUSINESS WIRE)–New research released today by Medallia, Inc., the global leader in customer and employee experience, reveals that 38% of hospitality workers say they’re considering or already have plans to leave their jobs in the next two months. This and other insights are available in the full report, Global Staffing Report: Employee Experience Impacts Hospitality, released today by Medallia Zingle, the leading intelligent messaging provider used by some of the world’s biggest hospitality brands.

medallia colorlogo

For the report, Medallia surveyed more than 1,250 travel and hospitality workers from the United States, United Kingdom, France, Spain & Germany. Findings reveal major challenges affecting the hospitality industry today, including how the return to travel is impacting workers’ job satisfaction, their employee experience, and their relationships with guests.

With hospitality’s historic staffing shortage well-reported, the report’s uncovering that nearly two-fifths of global hospitality workers plan to leave their jobs by the end of the year — and that 59% of organizations are working with less staff now than they did prior to the pandemic — hints at a challenging holiday season ahead for brands across the world. In fact, the study found that while 67% of workers report that their organization is experiencing increased guest activity since the return to travel, nearly half (48%) say their employers’ handling of it has been “Just OK.”

This is worrying news at a crucial juncture in the industry’s reopening, but illustrates the opportunity that exists for brands to better equip their teams to handle the upcoming travel surge, and address the industry’s staffing crisis.

“All industries have been affected by the COVID-19 crisis, but the travel and hospitality sector has experienced a particularly significant impact on its operations,” said Ford Blakely, founder, senior vice president and general manager of Medallia Zingle. “And while it’s concerning that a significant amount of workers are considering or already have plans to leave their jobs before the end of the year, brands have a massive opportunity to adopt technology and communication strategies that allow their employees to do more with less and create a more empowered and engaged workforce that’s enthusiastic about providing their guests with a best-in-class experience.”

Additional highlights from the report include:

  • US’ Struggles Higher Than Global Average: 68% of U.S. hospitality workers say their organization is working with less staff now than they did prior to the pandemic.

    • Top 3 reasons globally: “health and safety concerns,” “lack of job security,” and because “workers obtained new jobs during the shutdown.”
  • Little Payoff for Employees: 61% of hospitality workers across the globe say their roles are harder and less rewarding since the onset of the pandemic.
  • Employee Experience Takes a Hit: A quarter (24%) of employees say that their employee experience has gotten worse and that they feel less engaged.

    • Additionally, 27% say that the customer experience they are providing has also gotten worse since the onset of the pandemic.
  • Hiring Woes Persist: More than half (52%) of hospitality employees across the globe say that hiring talent has been an issue for their organization.

    • Top 3 reasons: “not enough qualified applicants,” “lack of resources to offer competitive pay or benefits,” and “lack of flexibility/remote options.”

Medallia Zingle’s full “Global Staffing Report: Employee Experience Impacts Hospitality” report can be downloaded here.

About Medallia

Medallia is the pioneer and market leader in customer, employee, citizen and patient experience. The company’s award-winning SaaS platform, Medallia Experience Cloud, is becoming the experience system of record that makes all other applications customer and employee aware. The platform captures billions of experience signals across interactions including all voice, video, digital, IoT, social media and corporate messaging tools. Medallia uses proprietary artificial intelligence and machine learning technology to automatically reveal predictive insights that drive powerful business actions and outcomes. Medallia customers reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment. For more information visit www.medallia.com.

© 2021 Medallia, Inc. All rights reserved. Medallia®, the Medallia logo, and the names and marks associated with Medallia’s products are trademarks of Medallia. All other trademarks are the property of their respective owners.


PR Contact:
Eric Stoessel


IR Contact:
Carolyn Bass


Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy in Observational BICSTaR Study Demonstrate Consistent Efficac OutBuro lgbt professional entreprenuer networking community

Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting

– Clinical Data Across a Diverse Range of People Living With HIV on Biktarvy Treatment in the International BICSTaR Study Showed High Effectiveness and High Levels of Adherence –

– Long-Term Switch Data Presented at EACS 2021 Further Establish the Robust and Durable Efficacy Profile of Biktarvy –

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, which is designed to evaluate the antiviral effectiveness and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in 1,135 people living with HIV. The BICSTaR study also collected patient-reported outcomes in routine clinical practice to better understand the impact of treatment on health-related quality of life in people living with HIV. These data were presented at the 18th European AIDS Conference (EACS 2021).

Gilead presented an analysis of patient-reported outcomes after 12 months of treatment with Biktarvy from the BICSTaR study. During the study, conducted at sites in Europe, Canada and Israel, people living with HIV who initiated treatment with Biktarvy between June 2018 and September 2020 completed questionnaires at baseline and 12 months. The questionnaires assessed patient-reported outcomes covering a range of measures. The results underline the importance of collecting patient-reported outcomes in order to understand the impact on mental health status, health-related quality of life and treatment satisfaction of people living with HIV.

Despite advances in antiretroviral therapy, people living with HIV experience burdensome multidimensional symptoms and concerns requiring person-centered care,” said Fernando Bognar, MD, Vice President, Medical Affairs, HIV at Gilead Sciences. “The patient-reported outcomes observed in the BICSTaR study provide a first-hand assessment of the impact of HIV treatment and care on the quality of life that people living with HIV experience. As physicians and people living with HIV look to understand what long-term treatment means to them individually, these data presented at EACS also reinforce that Biktarvy can meet the specific treatment needs of diverse groups of people, including men and women aging with HIV and those with existing comorbid conditions.”

In a second analysis of the BICSTaR study, 97% (n=149/154) of treatment-naïve adults and 96% (n=771/800) of treatment-experienced adults achieved and maintained virologic suppression (HIV-1 RNA <50 copies/mL) after one year of treatment. Participants included adults 50 years of age or older, cisgender women, and late presenters (CD4 <200 cells/μl and/or ≥1 AIDS-defining event at baseline). Both treatment-naïve and treatment-experienced participants had high persistence with Biktarvy (91%, n=1032/1135) across both groups, Biktarvy was generally well-tolerated and no resistance to the components of Biktarvy emerged. 148 (13%) participants had any adverse event and 2 (<1%) had a serious adverse event. The most common drug-related adverse events observed to date in the BICSTaR study were weight increase (3%), nausea (1%), depression (1%), headache (1%), fatigue (1%), diarrhoea (1%) and sleep disorder (1%). These large cohort findings continue to reinforce the real-world effectiveness of Biktarvy across populations and are consistent with evidence from randomized clinical trials.

Additional Biktarvy data presented at EACS 2021 include a Phase 3 trial (Study 1878) that demonstrated the durable efficacy of Biktarvy. In the study, 99% of people living with HIV who switched to Biktarvy from a boosted protease inhibitor-based regimen maintained and achieved long-term viral suppression through a median of 101 weeks (n=525/532), including 98% of participants with pre-existing resistance (n=212/217; median of 108 weeks) and 98% of participants with viral blips (n=39/40; median of 109 weeks), with no treatment-emergent resistance to Biktarvy. A pooled analysis of five Phase 3 studies (1844, 1878, 4030, 4449, 4580) also found that regardless of pre-existing TAMS (thymidine analog-associated mutations M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E), a high proportion of those on Biktarvy were able to maintain virologic suppression and had an absence of treatment-emergent resistance. These data support the continued evaluation of Biktarvy as a potential option for virologically suppressed people living with HIV with known resistance. The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational, and the safety and efficacy of Biktarvy for this use have not been established.

Please see below for the U.S. Indication and Important Safety Information, including Boxed Warning, for Biktarvy.

There is currently no cure for HIV or AIDS.


The Bictegravir Single Tablet Regimen (BICSTaR) Study is an ongoing, multinational, observational single-arm, non-comparative real-world cohort study, which aims to evaluate the effectiveness, safety, tolerability, and patient-reported outcomes of treatment with Biktarvy in treatment‐naïve and treatment‐experienced people living with HIV. Among the people living with HIV enrolled in the BICSTaR study, there is a high baseline prevalence of comorbidities.

About Biktarvy

Biktarvy is a complete HIV-1 treatment that combines three powerful medicines to form the smallest integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available, offering simple once-daily dosing with or without food, with a limited drug interaction potential and a high barrier to resistance. Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone. Biktarvy is a complete single-tablet regimen and should not be taken with other HIV-1 medicines.

In February 2018, the U.S. Food and Drug Administration (FDA) approved Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a once-daily single-tablet regimen for the treatment of HIV-1 infection in adults. In June 2019, the FDA approved labeling revisions to Biktarvy, expanding the patient population to include pediatric patients weighing at least 25 kg. In October 2021, the FDA approved a new low-dose tablet formulation of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg. For all patient populations, Biktarvy is only indicated for the treatment of HIV-1 infection in people who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

U.S. Important Safety Information for Biktarvy


  • Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted.


  • Coadministration: Do not use BIKTARVY with dofetilide or rifampin.

Warnings and precautions

  • Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions.
  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
  • New onset or worsening renal impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)–containing products. Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min except in virologically suppressed adults <15 mL/min who are receiving chronic hemodialysis. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.

    Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.
  • Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse reactions

  • Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were diarrhea (6%), nausea (6%), and headache (5%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for BIKTARVY for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
  • Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of BIKTARVY. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of BIKTARVY. BIKTARVY can increase the concentration of drugs that are substrates of OCT2 or MATE1.
  • Drugs affecting renal function: Coadministration of BIKTARVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.

Dosage and administration

  • Dosage: Adult and pediatric patients weighing ≥25 kg: 1 tablet containing 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), and 25 mg tenofovir alafenamide (TAF) taken once daily with or without food. Pediatric patients weighing ≥14 kg to <25 kg: 1 tablet containing 30 mg BIC, 120 mg FTC, and 15 mg TAF taken once daily with or without food. For children unable to swallow a whole tablet, the tablet can be split and each part taken separately as long as all parts are ingested within approximately 10 minutes.
  • Renal impairment: For patients weighing ≥25 kg, not recommended in patients with CrCl 15 to <30 mL/min, or <15 mL/min who are not receiving chronic hemodialysis, or <15 mL/min who are receiving chronic hemodialysis and have no antiretroviral treatment history. For patients weighing ≥14 kg to <25 kg, not recommended in patients with CrCl <30 mL/min.
  • Hepatic impairment: Not recommended in patients with severe hepatic impairment.
  • Prior to or when initiating: Test patients for HBV infection.
  • Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus.

Pregnancy and lactation

  • Pregnancy: There is insufficient human data on the use of BIKTARVY during pregnancy. Dolutegravir, another integrase inhibitor, has been associated with neural tube defects. Discuss the benefit-risk of using BIKTARVY during pregnancy and conception. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
  • Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

U.S. Indication for Biktarvy

Biktarvy is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed eleven HIV medications, including the first single tablet regimen to treat HIV and the first once-daily oral antiretroviral tablet for pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection. These advances in medical research have helped to transform HIV into a preventable, chronic condition for millions of people.

Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships and collaborations, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere.

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, including those involving Biktarvy; the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Biktarvy; Gilead’s ability to receive FDA and other regulatory approvals for additional indications for Biktarvy, and the risk that any such approvals, if granted, may have significant limitations on its use; the risk that physicians may not see the benefits of prescribing Biktarvy; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. full Prescribing Information for Biktarvy and Descovy, including BOXED WARNINGS, are available at www.gilead.com.

Biktarvy, Descovy, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks are the property of their respective owner(s).

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.


Jacquie Ross, Investors

(408) 656-8793

Brian Plummer, Media

(202) 309-5207

VTS Announces Margaretta Noonan as New Chief People OfficerOutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary

VTS Announces Margaretta Noonan as New Chief People Officer

Seasoned SaaS HR leader with over 30 years of experience as a people and talent leader is tapped to provide employees a best-in-class experience

NEW YORK–(BUSINESS WIRE)–VTS—the commercial real estate industry’s (CRE) leading leasing, marketing, asset management, and tenant experience platform, today announced that Margaretta Noonan has been appointed as the company’s new Chief People Officer. The announcement comes at a time when VTS has made major capital investments in its workforce during the pandemic, and as the company continues to grow rapidly at scale, with its most successful year to-date.

VTS Logo

Noonan, an accomplished executive with over 30 years of experience as a people and talent leader in SaaS and public technology companies, has a proven track record of scaling talent and culture for high-growth internet technology businesses. Previously, Noonan led HR for several top global public companies including Monster and Hudson; additionally, she founded her own human resources/people consulting practice. At VTS, she will lead the charge of rapidly growing the VTS team – nearly 500 employees, and shaping VTS’ employee experience, a role she has been serving in an interim capacity for over a year. Under her leadership, VTS has navigated through the complexities of a global pandemic and supported its workforce in a compassionate way as they face unprecedented anxieties – all while growing the global employee base at remarkable scale. Since joining VTS, Noonan has seen the company headcount grow by 65% and has been instrumental in helping VTS secure a number of awards, most recently Fortune’s Best Workplaces in New York City.

For over a year, Margaretta has proven to be an asset of the utmost value to VTS as we continue to grow our business at an unprecedented rate, while steering us through the challenges posed by the pandemic and remote work,” said Nick Romito, Chief Executive Officer of VTS. “As a company, VTS considers providing best-in-class employee experience a top priority. With her impressive career and knowledge of VTS’ culture, it was clear that Margaretta was the best fit for the appointment to continue growing and supporting our workforce.”

As a people and talent professional, this has been an incredible time to join VTS, helping to shape their response to the COVID-19 pandemic by providing the highest level of support possible to employees, while also helping them navigate the challenges of growing their workforce, including an acquisition, while many people are still working remotely,” said Noonan. “Throughout my career I’ve believed in a people-first approach to business, and VTS knows the importance people have in shaping the future and success of the company. As the new Chief People Officer, I look forward to continuing working with the terrific VTS People Team to further build the industry-leading diverse culture VTS is recognized for.”

VTS, known for its exceptional workplace culture, recently received a Great Place to Work Certification™ in June 2021. The global authority on workplace culture, employee experience, and leadership behaviors recognized the company for its competitive perks package, work-life balance, investments in its people, DEI (diversity, equity, and inclusion), support for employees outside of work, and company leadership. In the certification, 95% of employees said VTS is a great place to work which is 4 points higher than average U.S. companies recognized.

VTS continues to experience rapid growth, and is actively hiring within various roles throughout the organization. Visit vts.com/careers to learn more.

About VTS

VTS is commercial real estate’s leading leasing, marketing, asset management, and tenant experience platform where the industry comes to make deals happen and real-time data comes to life. The VTS Platform captures the largest first-party data source in the industry, which delivers real-time insights that fuel faster, more informed decision making and connections throughout the deal and asset lifecycle. VTS Data, the industry’s only forward-looking market dataset, and VTS Market and Marketplace, the industry’s first integrated online marketing solution, give landlords, brokers, and tenants unparalleled visibility into real-time market information and the direct connectivity to execute deals with greater speed and intelligence at every point in the planning, marketing, leasing, and asset management cycle. VTS Rise is the industry’s most comprehensive tenant experience solution, offering occupiers, building operators, and visitors an immersive, tech-enabled experience.

More than 60% of Class A office space in the US and 12B square feet of office, retail, and industrial real estate globally is managed on the VTS platform. VTS’ user base includes over 45,000 CRE professionals including respected industry leaders like Blackstone, Brookfield Properties, LaSalle Investment Management, Hines, Boston Properties, Oxford Properties, JLL, and CBRE. To learn more about VTS, and to see our open roles, visit www.vts.com.



Eric Johnson



OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Illinois HIV Care Connect Launches HIV Innovation Campaign

SPRINGFIELD, Ill.–(BUSINESS WIRE)–#GTZIL–Illinois HIV Care Connect today launched its HIV Innovation web and social media campaign, showcasing several Illinois HIV initiatives that are helping to prevent or treat HIV more effectively.

Articles about five initiatives so far are located on the HIV Innovation page of hivcareconnect.com. The page features the Getting to Zero Illinois HIV Dashboard, the Central Illinois Friends organization, the Transgender Women Involved in Strategies for Transformation (TWIST) intervention being implemented by the Community Wellness Project in E. St. Louis, RuralHarmony‘s outreach and research effort, and Cicero’s Corazón Community Services. More articles will be added in the coming months.

The #HIVInnovation campaign will be visible on Illinois HIV Care Connect’s Twitter, Facebook and Instagram social media platforms. A quiz relating to the five initiatives offers an easy way to understand how innovative programs are improving the lives of persons living with HIV in Illinois.

The HIV Innovation campaign is Illinois HIV Care Connect’s eighth annual quality improvement initiative, following programs on HIV stigma, HIV and youth, social determinants of health, HIV treatment as prevention, viral suppression, staying in HIV care, and HIV and mental health.

“We chose HIV Innovation to celebrate the important role Illinois continues to play in the HIV arena,” said Jeffery Erdman, the associate executive director of the Illinois Public Health Association, which administers the Illinois HIV Care Connect program. “Illinois is a hub for leading HIV research, legislation, outreach and communication. Throughout the state, we continue to see remarkable innovations in virtually all aspects of HIV prevention and treatment.” Illinois HIV Care Connect is funded by the Illinois Department of Public Health.

About Illinois HIV Care Connect

Illinois HIV Care Connect is a statewide network providing medical case management, health care and support services to people living with HIV. Illinois HIV Care Connect’s eight lead agency offices serve people living with HIV in all of Illinois’ 102 counties. https://hivcareconnect.com


Ray Valek, ray@valekco.com, 708-352-8695

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Dare Worldwide: Inclusivity Key to Organizational Performance

  • Company leaders say 85% of performance indicators are unreliable
  • Company leaders give their companies low ratings on purpose, connection and collaboration
  • Employees value trust, engagement and communication. Businesses favor rapid adaptation to technology to drive job performance.

WASHINGTON–(BUSINESS WIRE)–Business transformation experts Dare Worldwide, in collaboration with communications agency GCM, have unveiled research showing 85% of performance metrics are not linked to sustainable company performance.

Dare Worldwide

The State of Leadership, Culture and Purpose study, surveyed 1,000 managers at midsize to large companies in the US, measuring the processes and values that impact productivity, growth and employee experience. The study found company leaders gave their companies low ratings regarding purpose, connection, and collaboration, which are key to long term sustainability.

In the poll, employees said their companies do well in seven key performance indicators, but none of these were considered to have a positive impact on company performance. Only one performance indicator, purpose, strongly correlates with positive employee experience, yet 35% of respondents thought their company was underperforming in this metric.

Trust, engagement and communicating effectively were considered by respondents to create a positive employee experience. Yet these assets were not considered to drive company performance over the next five years.

Commenting on the findings, Rita Trehan, CEO of Dare Worldwide, said:

“Companies are prioritising expediency and rapid technology adoption, at the expense of purpose and inclusivity which are the key drivers of company performance. Businesses must incorporate inclusivity to achieve sustainable growth.”

The research also shows that employees above the director level are 50% more likely to think people within their organization have the same understanding of their business identity than those below their level.

This suggests there’s a disconnect in the messages sent to the company by the leadership. “This research is raising a red flag for communications leads at medium and large organizations,” said Zach Giglio, CEO of GCM. “Organizations not aligned on their identity internally are limited in their ability to communicate effectively with external stakeholders and, ultimately, drive growth, impact and revenue.”

The research was launched as Rita Trehan launches an online diagnostic tool in which companies measure their inclusivity and purpose.


Report and methodology available on request.


Alexander Clare


C (44 )77922 54143

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Bi.org Celebrates 25th Anniversary in Time for Bi-Pride Month and Bi-Visibility Day – Foundational Bi-Resource Commemorates Two Decades of Supporting Inclusivity Across the (Bi)Sexuality Spectrum

Now featuring bilingual content, with a wealth of articles, Bi 101s, and other info available both in Spanish and English.

LOS ANGELES, Sept. 21, 2021 /PRNewswire/ — Bi.org proudly announced their 25th anniversary celebration in tandem with the annual Bi-Pride Month, and Bi-Visibility Day set for September 23. With over 1.3 million page-likes on Facebook as well as substantial Twitter and Instagram followings, Bi.org maintains its position as the largest online resource for Bi information and news. Originally founded in the 1990s as a research project for the American Institute of Bisexuality and The Klein Sexual Orientation Grid (KSOG), Bi.org continues to serve a population that is as diverse as it is inclusive.

AIB and bi.org founder Fritz Klein
AIB and bi.org founder Fritz Klein

“We’re happy that our founder’s work, psychiatrist Fritz Klein, is still going strong,” said Talia Squires, Director of Bi.org. “He originally created Bi.org as an online community to post news, host forums and dating profiles, and create an inclusive global hub for the underserved Bi population. People who, like many in the LGBT community, often had to live their lives in the shadows. But Klein lived his life proudly, out, and wanted the rest of the world to have the same freedom. Thankfully, times have changed, and over the years, acceptance has allowed Bi social media groups and dating sites to thrive. So while Bi.org maintains a thriving community, it also continues to publish important informative articles and resources, inspiring profiles of famous Bi people, and Bi character profiles to help fill everyday Bi folks with hope. Our core message is still the same – you are not alone.”

For important Bi-related news and content, visit Bi.org online. And keep an eye out for the Spanish Bi.org newsletter, set to launch in 2022. Follow Bi.org on social media @BiDotOrg: FacebookTwitterInstagram.

About Bi.org

Originally founded in 1996 by sex researcher and psychiatrist Fritz Klein, Bi.org (formerly bisexual.org) began with the simple goal of letting Bi people know they were not alone. When first launched, there were almost no online resources for the Bi community, or those resources were hard to find, highly sexualized, and/or catered to niche audiences. Since those early years, Bi.org has evolved to serve an increasingly diverse, global community.

Bi Pride Month
Bi Pride Month

Over two decades later, Bi.org continues its mission to connect Bi people around the world; providing accessible and scientifically accurate information about (bi)sexuality. Whether visitors need to learn about (bi)sexuality to better understand themselves, loved ones, peers, or conduct research – Bi.org will continue to offer valuable resources. Learn more about the global Bi community at: www.Bi.org.

Media Contact:

Talia Squires, Director of Bi.org


OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Atlanta City Council District 6 Candidate Alex Wan Receives Highest Score from Committee for a Better Atlanta

Alex Wan, seeking to again represent CDE6 after doing so for two successful terms (2010-2018) garners highest rating of “excellent” from influential group

ATLANTA, Sept. 22, 2021 /PRNewswire/ — Former Atlanta City Council member Alex Wan, a long-time Morningside homeowner and civic leader, has received the highest rating of “Excellent” from the Committee for a Better Atlanta (CBA). CBA is a coalition of businesses and civic organizations whose mission is to foster a healthy business environment by advocating a common business and civic agenda to policymakers as well as citizens.

Alex Wan, candidate for Atlanta City Council District 6
Alex Wan, candidate for Atlanta City Council District 6

“I am honored to again receive this acknowledgment from the CBA, a group of respected members of Atlanta’s business community and civic leaders who recognize the need for thoughtful, business-minded civic leaders engaged in City government,” Wan says. “With the issues facing our City and a time of transition at City Hall, I am ready to hit the ground running as the experienced leader District 6 needs.”

Wan’s score of 91 out of 100 was the highest in the field in the District 6 race. In his 2009 and 2013 Council races, Wan also was rated excellent and placed at the top of his field of opponents. All current CBA scores and ratings can be seen here www.CBATL.org.

“The rating of ‘Excellent’ is an acknowledgement that Alex continues to be a smart and dedicated leader whose experience, accessibility, transparency and collaborative leadership are what is needed now for the neighborhoods across City Council District 6,” says Phil Kent, former Turner Broadcasting System CEO.

He also notes that, “CBA leaders understand the importance of addressing issues Alex champions – from neighborhood safety to efficient and effective city services. Their rating indicates they know Alex has the strength, depth and experience to again represent all of his neighbors across the District on City Council.”

The Committee for a Better Atlanta’s decision is based upon written and oral responses from all candidates in the municipal races. The score is based on key areas, including public safety, financial competence, ethics/transparency, transportation, affordable housing and arts, among others. The ranking of candidates – on a four-tier scale – judges the qualifications of all Atlanta candidates.

Wan was first elected to the City Council District 6 post in 2009 and easily earned a second term in 2013. He is the first Asian American and first openly gay man to serve on Atlanta City Council. Raised in Atlanta and a District 6 and Morningside homeowner for 27 years, Wan was perhaps best known before his Council wins for deep roots in the community and long-time civic leadership.

Committee for a Better Atlanta 2021 scores
Committee for a Better Atlanta 2021 scores

“I look forward to continuing to fight alongside friends and neighbors across the district for our shared issues, including public safety, city service delivery, and quality of life initiatives,” Wan says. “Voters know I’m accessible and that my prior experience on the Atlanta City Council and relationships I have across the District and City are invaluable.”

He is Executive Director of Horizons Atlanta, a nonprofit that provides tuition-free summer enrichment programs for children from traditionally underserved communities. His professional experience includes the private, public, non-profit and higher-education sectors.

Atlanta City Council District 6 includes much of intown northeast Atlanta. For more information about Wan and his campaign or to contribute: www.AlexWanForAtlanta.com.

Media contact:
B. Andrew (Drew) Plant

SOURCE Alex Wan for Atlanta

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

BEYOND DIVERSITY: 12 Non Obvious Ways to Build a More Inclusive World By Rohit Bhargava and Jennifer Brown

Can one book help to build a more fair and inclusive world? This one can.

NEW YORK, Sept. 22, 2021 /PRNewswire/ — In Beyond Diversity: 12 Non Obvious Ways to Build a More Inclusive World, best-selling authors Rohit Bhargava and Jennifer Brown team up to tackle some of society’s most pressing challenges: dismantling racism, oppression and exclusion and building acceptance and understanding across differences. They achieve this through storytelling and a focus on intersectional perspectives and voices. 

A book about how to build a more inclusive world. Coming November 9, 2021. Visit www.nonobviousdiversity.com/media for more information and resources.
A book about how to build a more inclusive world. Coming November 9, 2021. Visit www.nonobviousdiversity.com/media for more information and resources.

BEYOND DIVERSITY: 12 Non Obvious Ways to Build a More Inclusive World can help build a more fair and inclusive world.Tweet this

Beyond Diversity, available November 9, 2021, is inspired by the inaugural Non-Obvious Beyond Diversity Summit in January 2021. More than 200 DEI champions from around the globe came together at the virtual summit to share their stories, including casting directors, bookstore owners, disability community leaders, healthcare professionals, students, VCs, standup comedians, chief diversity officers, pro gamers, archaeologists, government insiders, startup founders, and even a master puppeteer. Over 75 percent of them identified as belonging to an underrepresented group and more than two-thirds identified as a gender other than male. The range of expertise and topics represented was equally diverse.  

Their stories are sure to create moments of awareness and awakening. With real life testimony they show how each of us, no matter our background or identity, can have an impact and drive change in the world.

Beyond Diversity takes readers on an educational journey and lifts the lid on how bias and privilege have benefitted a few at the expense of the many. The book offers an ambitious look at diversity, equity, and inclusion through the lens of twelve specific themes: storytelling, identity, family, culture, education, retail, workplace, technology, entrepreneurship, leadership, government, and the future. Each chapter paints a revealing picture of our world, the potential for change and what actions will help us get there.

The book is a call to action and Bhargava and Brown challenge each of us to build bridges to a more authentically diverse and equitable future. This is a book about being more than a bystander. It provides a much-needed directive for stepping off the sidelines and getting involved. The only way to enact change is to inspire bystanders to take action. For former bystanders, and DEI experts alike, this book offers a blueprint for action to create a more inclusive world for everyone.

With the ongoing global focus on inclusion and equity and the fast-moving shifts across society, Beyond Diversity provides relevant and timely expertise for individuals, organizations and leaders. The book’s insights guide readers to compassionately and effectively respond to the deeply entrenched divisions, disparities and inequities that are prevalent across the world. 

Beyond Diversity is currently available for pre-sale and will become available for sale on November 9, 2021. Visit nonobviousdiversity.com/media to download the book excerpt, join the launch team and access other media resources.

Advance Praise for Beyond Diversity

“Thought-provoking, layered and fresh. Each one of us has a part to play in creating a more inclusive world. Wherever you may be in your journey, Beyond Diversity is the weapon in your DEI arsenal. For the non-believers, bystanders, and uninitiated—be inspired to make better inclusion choices. For the believers, advocates, and experts—be rejuvenated in your fight for equity.”   —MICHELLE KING, Author of The Fix and CEO of Equality Forward

“Beyond Diversity is an urgently needed, eminently practical book that every leader should read. Bhargava and Brown have taken on a tough topic with sharp minds and open hearts. In a dozen crisp and fascinating chapters, they show how to move past mere sentiment to bring genuine inclusion into action.” —DANIEL H. PINK, New York Times bestselling author of When, Drive, and To Sell Is Human 

“Jennifer and Rohit have artfully used the power of storytelling to connect the reader with the lived experience of LGBTQ+ people and other marginalized communities that have been systematically discriminated against and ‘othered’ for far too long. We must build a society that is more inclusive of transgender and non-binary people and honors their contributions and realities. Their book opens eyes, hearts, and minds!” —AMBER HIKES, Chief Equity and Inclusion Officer, American Civil Liberties Union (ACLU)

About the Authors

ROHIT BHARGAVA (he/him/his) is on a mission to help the world be more open-minded by teaching others how to be non-obvious thinkers. He is the founder of the Non-Obvious Company and previously spent 15 years leading brand strategy for large global brands while at Leo Burnett and Ogilvy. Rohit is the Wall Street Journal bestselling author of six books and is a popular Adjunct Professor of storytelling, persuasion, and marketing at Georgetown University.  

JENNIFER BROWN (she/her/his) is an award-winning entrepreneur, speaker, author, and diversity and inclusion expert who is deeply passionate about building more inclusive workplaces where more of us can feel welcomed, valued, respected, and heard. As the Founder and CEO of Jennifer Brown Consulting (JBC), a certified woman- and LGBT-owned firm, Jennifer and her team design and execute inclusion strategies that have been implemented by some of the biggest companies and nonprofits in the world. She is also the bestselling author of two books, Inclusion: Diversity, The New Workplace and The Will to Change (2017) and How To Be An Inclusive Leader: Your Role in Creating Cultures of Belonging Where Everyone Can Thrive (2019).

Retail Price: $19.95 • Published 11/09/2021 in Paperback + Ebook + Large Format Print + Audio Book • ISBN – 978-1940858968 www.nonobviousdiversity.com

Mara Silverio, media@bdaviscomm.com

SOURCE Non-Obvious Diversitymt